Invion Ltd (ASX: IVX) Share Price and News

Price

$0.098

Movement

0.007 (-6.67%)

As at 17 Apr - Closed (20 mins delayed)

52 Week Range

$0.095 - $0.60

 
1 Year Return

-80.4%

Invion Ltd Chart and Price Data

2025
2025
2025
2025
$0.00
$0.25
$0.50
$0.00
$0.25
$0.50
$0.00
$0.25
$0.50
$0.00
$0.25
$0.50

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $7.59 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 77.48 million
Earnings per share -0.108
Dividend per share N/A
Year To Date Return -62.50%
Earnings Yield N/A
Franking -
Earnings Yield

N/A

Franking

-

Dividend per share

N/A

Year To Date Return

-62.50%

Shares Outstanding

77.48 million

Earnings per share

-0.108

Share Price

$0.098

Day Change

0.007 (-6.67%)

52 Week Range

$0.095 - $0.60

Yesterday's Close

$0.105

Today's Open

$0.10

Days Range

$0.098 - $0.10

Volume

123,426

Avg. Volume (1 month)

74,780

Turnover

$12,338

As at 17 Apr - Closed

Invion Ltd (ASX: IVX)
Latest News

Doctor doing a telemedicine using laptop at a medical clinic
Share Gainers

This small-cap ASX healthcare stock just exploded 131%! Here's why

Investors are sending the ASX small-cap healthcare stock soaring on Tuesday.

Read more »

asx share price increase represented by golden dollar sign rocketing out from white domes of lithium
Healthcare Shares

Invion share price (ASX:IVX) rockets 123% on pilot study results

The company's shares are rocketing to a multi-year high today.

Read more »

a woman
Share Gainers

Why the Invion share price rocketed 225% higher today

The Invion Ltd (ASX:IVX) share price is rocketing higher on Wednesday. Here's why...

Read more »

a woman
Share Gainers

Why the Invion share price zoomed 86% higher today

The Invion Ltd (ASX:IVX) share price almost doubled in value this morning after releasing an update on IVX-P02...

Read more »

a woman
Investing

Here's why Invion Ltd stock plunged 24.4% today

Invion Ltd (ASX:IVX) is a small-cap drug developer which has lost 62% of its value since August

Read more »

IVX ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
8th Apr 2025 2025-04-08T08:48:16 Notice of Extraordinary General Meeting/Proxy FormYesNo8:48am301.4M
1st Apr 2025 2025-04-01T08:44:40 Section 708A Cleansing StatementYesNo8:44am2191k
1st Apr 2025 2025-04-01T08:39:45 Application for quotation of securities - IVXYesNo8:39am616k
13th Mar 2025 2025-03-13T14:57:56 Section 708A Cleansing StatementYesNo2:57pm2191k
13th Mar 2025 2025-03-13T14:51:01 Application for quotation of securities - IVXYesNo2:51pm616k
11th Mar 2025 2025-03-11T15:20:38 Update - Proposed issue of securities - IVXYesNo3:20pm620k
5th Mar 2025 2025-03-05T09:32:28 Cancel - Application for quotation of securities - IVXYesNo9:32am616k
5th Mar 2025 2025-03-05T09:21:48 Share Purchase Agreement Termination and Tranche RepaymentYesNo9:21am2185k
4th Mar 2025 2025-03-04T14:49:48 Section 708A Cleansing StatementYesNo2:49pm2191k
4th Mar 2025 2025-03-04T14:48:18 Application for quotation of securities - IVXYesNo2:48pm616k

About Invion Ltd

Invion Ltd is an Australian clinical-stage pharmaceutical drug development company. It is engaged in the development of PhotoDynamic Therapy (PDT) for cancer treatments called Photosoft, for the treatment of a range of cancers and infectious diseases. The company produces topical and intravenous products suitable for use in skin cancer and solid tumors, such as ovarian, prostate, and lung cancer. Invion has developed a portfolio of patent protected compounds. Its drug candidate is INV043, a novel photosensitiser which has the potential to work as a therapy and a diagnostic tool.

IVX Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
17 Apr 2025 $0.10 $-0.01 -9.52% 123,426 $0.10 $0.10 $0.10
16 Apr 2025 $0.11 $0.01 10.31% 91,648 $0.11 $0.11 $0.10
15 Apr 2025 $0.10 $0.00 0.00% 4,379 $0.10 $0.10 $0.10
14 Apr 2025 $0.10 $0.00 0.00% 58,587 $0.11 $0.11 $0.10
11 Apr 2025 $0.11 $0.00 0.00% 36,906 $0.11 $0.11 $0.11
10 Apr 2025 $0.10 $0.00 0.00% 26,640 $0.10 $0.10 $0.10
09 Apr 2025 $0.10 $0.00 0.00% 1,834 $0.10 $0.10 $0.10
08 Apr 2025 $0.10 $-0.01 -9.52% 24,360 $0.11 $0.11 $0.10
07 Apr 2025 $0.11 $0.00 0.00% 53,273 $0.10 $0.11 $0.10
04 Apr 2025 $0.11 $0.00 0.00% 186 $0.11 $0.11 $0.11
03 Apr 2025 $0.11 $0.00 0.00% 25,198 $0.11 $0.11 $0.11
02 Apr 2025 $0.11 $-0.01 -8.70% 125,194 $0.11 $0.12 $0.11
01 Apr 2025 $0.12 $0.02 20.00% 132,765 $0.11 $0.12 $0.11
31 Mar 2025 $0.10 $0.00 0.00% 134,489 $0.11 $0.11 $0.10
28 Mar 2025 $0.11 $-0.01 -9.09% 109,549 $0.11 $0.11 $0.11
27 Mar 2025 $0.11 $0.00 0.00% 4,323 $0.12 $0.12 $0.11
26 Mar 2025 $0.11 $-0.01 -8.70% 73,821 $0.11 $0.11 $0.11
25 Mar 2025 $0.12 $0.01 9.09% 11,308 $0.11 $0.12 $0.11
24 Mar 2025 $0.11 $-0.02 -16.00% 192,721 $0.12 $0.12 $0.11
21 Mar 2025 $0.13 $0.00 0.00% 20,598 $0.12 $0.13 $0.12
20 Mar 2025 $0.13 $0.01 8.33% 6,089 $0.12 $0.13 $0.12
19 Mar 2025 $0.12 $-0.01 -8.00% 325,148 $0.13 $0.13 $0.11

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
10 Dec 2024 Chiat Chew Issued 68,086 $17,021
Director remuneration.
10 Dec 2024 Alan Yamashita Issued 41,411 $10,352
Director remuneration.
10 Dec 2024 Alistair Bennallack Issued 37,647 $9,411
Director remuneration.
22 Oct 2024 Alistair Bennallack Cancelled 20,443,211 $40,886
Options expired.
04 Sep 2024 Alan Yamashita Exercise 10,864,187 $21,728
Exercise of options.
04 Sep 2024 Alan Yamashita Buy 10,864,187 $21,728
Exercise of options.
04 Sep 2024 Chiat Chew Exercise 17,861,942 $35,723
Exercise of options.
04 Sep 2024 Chiat Chew Buy 17,861,942 $35,723
Exercise of options.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Ms Melanie Jaye Leydin Non-executive directorCompany Secretary Aug 2024
Ms Leydin has over 30 years experience in the accounting profession and over 20 years experience holding Board positions including Company Secretary of ASX listed entities. She has experience in relation to public company responsibilities, including ASX and ASIC compliance, control and implementation of corporate governance, statutory financial reporting, reorganisation of Companies, initial public offerings, secondary raisings and shareholder relations.
Mr Chiat Thian Chew Chief Executive OfficerExecutive ChairmanExecutive Director Dec 2017
Mr Chew has over 25 years of experience in investing, finance and transforming business operations. He is Managing Partner at Polar Ventures, a private investment and consulting firm that provides capital, strategic and operating solutions, focusing on small to mid-sized enterprises in Asia. Mr Chew was previously an Executive Director at Goldman Sachs (Hong Kong and New York) responsible for the firm's proprietary investments including growth capital, private equity and special situations in both private and public companies. Mr Chew also held several positions in KPMG across Asia Pacific including Director at KPMG Consulting (Singapore and Sydney) where he led several large-scale operational restructurings, post-merger integration, transformation, and business performance improvement programs.
Mr Alan Yamashita Non-Executive Director Feb 2019
Mr Yamashita is a corporate consultant and investment professional, with over 40 years of experience in investment management, investment banking and alternative investment throughout the APAC region. From 1999 to 2005, Mr Yamashita was President and CEO of Search Investment Group and founding CEO and CIO of Search Alternative Investment Ltd (SAIL), a major private global hedge fund and private equity investment practice headquartered in Asia. Prior to Search Investments Group, Mr Yamashita was Managing Director and Head of Asia Capital Markets for Merrill Lynch from 1996 to 1998. Mr Yamashita is currently Managing Partner at Polar Ventures and has held positions as a 16-year veteran of Goldman Sachs and an advisor to various companies. He is a member of the Risk Committee.
Mr Alistair Bennallack Non-Executive Director Oct 2020
Mr Bennallack is currently the Group Chief Financial Officer of Village Roadshow Pty Ltd, Head of Risk for Village Roadshow Pty Ltd and Chief Executive Officer of Village Roadshow Theme Parks Asia, a division of Village Roadshow Theme Parks Pty Ltd. He is the primary executive responsible for conceptualizing, executing and delivering Village Roadshow's expansion into China and Asia. He is a former member of the Village Roadshow Ltd Executive Committee, current member of the Village Roadshow Theme Parks Executive Committee and current member of all Village Roadshow Pty Ltd's Management and Risk Committees. He is chair of risk committee.

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
Polar Ventures Limited 545,217,721 8.21%
BNP Paribas Nominees Pty Ltd Ib Au Noms Retail Client Drp> 528,480,596 7.96%
Rmwc Pty Ltd Rmwc Family A/C> 314,237,156 4.73%
Mr Honsue Cho 284,626,482 4.29%
Ngpdt Greater China Limited 272,652,297 4.11%
Mei Jun Lin 272,500,000 4.11%
Acslnc Pty Ltd Acslnc Family A/C> 224,610,000 3.38%
Ms Xiaoyi Wu Xiaoyi Wu Shanghai Commercial Bank Ltd A/C> 200,000,000 3.01%
Surfit Capital Pty Ltd 181,259,875 2.73%
Lind Global Fund Ii Lp 180,833,334 2.72%
Citicorp Nominees Pty Limited 153,690,429 2.32%
Shengli Wang 136,288,074 2.05%
Ms Xiaoyi Wu Xiaoyi Wu Interactive Brokers U7411855 A/C> 121,428,571 1.83%
Yong Chen 110,000,000 1.66%
Mr Yong Chen 93,253,079 1.40%
Ms Dandan Wang 82,819,526 1.25%
Mr Shengwei Ou 77,304,171 1.16%
Shubo Miao 73,333,333 1.10%
Mr Esmond Wong & Mrs Quynh Thi Kim Nguyen 67,564,765 1.02%
Eq Investment Pty Ltd 62,500,000 0.94%

Profile

since

Note